Zoetis Inc. (ZTS)
| Market Cap | 33.54B -51.9% |
| Revenue (ttm) | 9.53B +2.9% |
| Net Income | 2.67B +7.4% |
| EPS | 6.11 +11.0% |
| Shares Out | 419.23M |
| PE Ratio | 12.73 |
| Forward PE | 11.09 |
| Dividend | $2.12 (2.65%) |
| Ex-Dividend Date | Apr 20, 2026 |
| Volume | 1,830,756 |
| Open | 79.85 |
| Previous Close | 77.72 |
| Day's Range | 77.59 - 80.20 |
| 52-Week Range | 72.38 - 172.23 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 125.18 (+56.48%) |
| Earnings Date | May 7, 2026 |
About ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ZTS stock is "Buy." The 12-month stock price target is $125.18, which is an increase of 56.48% from the latest price.
News
Zoetis price target lowered to $112 from $145 at Citi
Citi lowered the firm’s price target on Zoetis (ZTS) to $112 from $145 and keeps a Buy rating on the shares. The firm cut the company’s estimates following the “difficult”…
Zoetis price target lowered to $115 from $160 at Morgan Stanley
Morgan Stanley analyst Erin Wright lowered the firm’s price target on Zoetis (ZTS) to $115 from $160 and keeps an Overweight rating on the shares.
Zoetis price target lowered to $99 from $130 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $99 from $130 and keeps a Neutral rating on the shares.
Zoetis price target lowered to $105 from $130 at Stifel
Stifel lowered the firm’s price target on Zoetis (ZTS) to $105 from $130 and keeps a Hold rating on the shares.
Zoetis price target lowered to $130 from $190 at JPMorgan
JPMorgan lowered the firm’s price target on Zoetis (ZTS) to $130 from $190 and keeps an Overweight rating on the shares.
Morning Movers: Planet Fitness and Zoetis sink after quarterly results
Futures are higher this morning, helped by another sharp decline in oil prices on optimism around a potential U.S.-Iran framework agreement. Crude dropping back toward the low-$90s is relieving pressu...
Zoetis Q1 ‘worse than it seems,’ says Stifel
Stifel notes that Zoetis (ZTS) Q1 organic operational revenue growth was flat versus the firm’s forecast for 2.4% growth and the Street’s 2.2% expectation. However, Zoetis’ results benefited from a…
Zoetis reports Q1 adjusted EPS $1.53, consensus $1.62
Reports Q1 revenue $2.3B, consensus $2.3B. “The first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting i...
Zoetis sees FY26 adjusted EPS $6.85-$7.00, consensus $7.03
Sees revenue $9.68B-$9.96B, consensus $9.89B.
Zoetis Is Today's Worst S&P 500 Stock. Here's Why.
The animal-health company missed first-quarter earnings estimates.
Zoetis Earnings Call Transcript: Q1 2026
Q1 2026 saw flat organic revenue and 1% adjusted net income growth, with strong international and livestock performance offsetting U.S. and companion animal declines. Guidance for 2026 expects 2%-5% organic revenue growth amid ongoing macro and competitive headwinds.
Zoetis Earnings release: Q1 2026
Zoetis released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Zoetis Slides: Q1 2026
Zoetis has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zoetis Quarterly report: Q1 2026
Zoetis has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zoetis Announces First Quarter 2026 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the first quarter of 2026. The com...
Notable companies reporting before tomorrow’s open
Notable companies reporting before tomorrow’s open, with earnings consensus, include McDonald’s (MCD), consensus $2.74… Howmet Aerospace (HWM), consensus $1.11… Datadog (DDOG), consensus 51c… Zoetis (...
Unusually active option classes on open May 1st
Unusual total active option classes on open include: Zoetis (ZTS), iShares DJ US Real Estate Index Fund (IYR), Carvana (CVNA), Datadog (DDOG), The Metals Company (TMC), BlackBerry (BB), Figma Inc…
Zoetis price target lowered to $130 from $136 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $130 from $136 and keeps a Neutral rating on the shares. The Q1 earnings outlook is cautious amid softer macro…
Zoetis Proxy statement: Proxy filing
Zoetis filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Zoetis Proxy statement: Proxy filing
Zoetis filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Zoetis Slides: Corporate presentation
Zoetis has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Pec...
Zoetis Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Revenue growth is projected at 3%-5% for 2026, led by parasiticides and supported by strong livestock performance. Long-acting therapies and new franchises in renal, oncology, and cardiology are expected to drive future growth, while AI and field team restructuring enhance operational efficiency.
Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital ...